This Web Site is committed to the memory of Janis Morrow.

Human liver             

Cirrhosis

2008

Back to information Index


Dec - Nov


AASLD: Mortality Risk in HCV-Positive Transplant Patients Similar Regardless of Donor Status

Higher SVR GENO 2 vs 3 Advanced Fibrosis- Cirrhosis 

Low SVR Tx-Naive Advanced- Fibrosis Cirrhosis 


 
Pegasys Maintenance in HALT-C

http://www.hcvadvocate.org/news/newsRev/2008/HJR-5.12.html
Nearly half of all people treated for chronic hepatitis C do not achieve a cure, and researchers are studying whether long-term low-dose pegylated interferon maintenance therapy can slow or prevent liver disease progression. Results from the largest such study, HALT-C, were published in the December 4, 2008 New England Journal of Medicine. A. DiBisceglie and colleagues initially treated chronic hepatitis C patients with advanced liver disease using standard-of-care 180 mcg/week pegylated interferon alfa-2a (Pegasys) plus weight-adjusted ribavirin. A total of 1,050 nonresponders and relapsers were then randomly assigned to receive either low-dose (90 mcg/week) Pegasys monotherapy or no ongoing therapy.

After 3.5 years, ALT levels, HCV viral load, and histological necroinflammatory scores decreased significantly in the treated patients. But there were no significant differences in rates of hepatocellular carcinoma, hepatic decompensation, fibrosis score increase of two or more points, or death (34.1% for the combined endpoint in the treatment arm vs. 33.8% in the untreated arm). Eight patients taking Pegasys maintenance therapy died, compared with two untreated participants. Percentages of patients with at least one serious adverse event were 38.6% and 31.8%, respectively (not quite statistically significant). The researchers concluded that, “Long-term therapy with peginterferon did not reduce the rate of disease progression in patients with chronic hepatitis C and advanced fibrosis, with or without cirrhosis, who had not had a response to initial treatment with peginterferon and ribavirin." Speaking to the media, Dr. DiBisceglie added, “To the extent there are still patients out there who are on this form of maintenance therapy, there is a real take-home message: It should be stopped.”

The HALT-C findings were surprising to many because reduced ALT and histological necroinflammatory activity – as seen in an interim analysis – were presumed to be markers for improved liver health. Contrary to these results, a smaller German study presented by S. Kaiser at the recent AASLD Liver Meeting (abstract 117) found that low-dose monotherapy with  0.5 mcg/kg/week pegylated interferon alfa-2b (PegIntron) for three or six years led to a "significant and persistent" decrease in fibrosis. While the debate over pegylated interferon maintenance continues, nonresponders considering this approach should be aware that directly targeted "STAT-C" drugs, expected to become available in a couple years, may offer a better option.

 

Hepatitis C treatment reduces the virus but liver damage continues

Treating patients who have chronic hepatitis C and advanced liver disease with long-term pegylated interferon significantly decreased their liver enzymes, viral levels and liver inflammation, but the treatment did not slow or prevent the progression of serious liver disease, a study finds.

These findings come from the clinical trial, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) and are reported in the Dec. 4 issue of the New England Journal of Medicine. HALT-C was funded by the National Institutes of Health (NIH) with additional support from Hoffmann-La Roche Inc.

"The results from HALT- C show without question that maintenance therapy with peginterferon does not prevent progression of liver disease among patients who have failed prior treatments," said James Everhart, M.D., project scientist for HALT-C in the Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), the principal sponsor of HALT-C at NIH. "These findings heighten the incentive to develop more effective drugs for patients with severe liver disease due to hepatitis C."

According to a press release issued by EurekAlert, Peginterferon therapy for up to 48 weeks is standard for chronic hepatitis C. But patients who do not have a sustained response to initial therapy have been given the drug over a longer time based on studies showing that this approach suppresses viral and enzyme levels, even if the virus is not completely eliminated. However, it was not known if long-term therapy would improve important clinical outcomes such as liver damage and death.

HALT-C, a randomized multicenter trial of 1,050 patients with chronic hepatitis C who had failed prior treatment to eradicate the infection, tested whether long-term treatment with peginterferon alfa-2a would reduce the development of cirrhosis, liver cancer, or liver failure. The 517 patients randomized to the treatment arm received 90 micrograms of peginterferon in weekly injections for 3.5 years. The 533 patients in the control arm underwent the same follow-up and care as the treated patients including liver biopsies, quarterly clinic visits and blood tests. All patients had advanced liver fibrosis, a gradual scarring of the liver that puts patients at risk for progressive liver disease and liver failure.

The outcomes studied in HALT-C were death, liver cancer, or liver failure, and for those who did not have cirrhosis initially, the development of cirrhosis. At the end of the study, 34.1 percent of the treated group and 33.8 percent of the control group had experienced at least one outcome. Patients in the treated group had significantly lower blood levels of the hepatitis C virus and improvement in liver inflammation. However, there was no major difference in rates of any of the primary outcomes between the groups.

Among treated patients, 17 percent stopped peginterferon after 18 months and 30 percent stopped the drug after two years. Infections, musculoskeletal or digestive problems were the most common reasons for stopping the drug.

According to HALT-C study chair and principal investigator Adrian M. Di Bisceglie, M.D., professor of internal medicine at Saint Louis University School of Medicine in Missouri, looking into how maintenance therapy works in non-responders is an important step. "Patients should not receive interferon as maintenance therapy for chronic hepatitis C. However, we can build on what was learned in HALT-C to identify better treatments that may delay or prevent liver damage in patients with advanced disease," he said.

The hepatitis C virus infects more than 100 million persons worldwide and as many as 4 million in the United States. Hepatitis C ranks with alcohol abuse as the most common cause of chronic liver disease and leads to about 1,000 liver transplants in the United States each year. The best current antiviral therapy of pegylated interferon given by injection in combination with oral ribavirin for about 6 months to a year eliminates the virus in about 50 percent of infected patients.

 

http://www.hindu.com/thehindu/holnus/099200812101522.htm

 

HealthWise: What We Eat


 

HealthWise: What We Eat
Lucinda Porter, RN

The U.S. National Day of Eating, affectionately known as Thanksgiving, is around the corner.  Between leftovers and football snacks, several days are spent consuming food.  This is followed by more holidays.  Food is everywhere – at work, the bank, even the health club. 

Champion eaters say that Thanksgiving is amateur day.  They don’t need a holiday to celebrate food.  If you are an amateur, you will go on a diet in January.  A pro extends the eating opportunity through Super Bowl Sunday.  The elite keep going through Valentine’s Day.

I am a champion eater.  However, as much as I love to eat, nothing tastes as good as feeling good feels. Over the years I have learned to balance my desire for food with my desire to be healthy.  Awareness is the cornerstone.  This means thinking about what I eat before I eat it, developing a practice, maintaining a commitment and getting back on track when I fall off. 

Food is the focus of this month’s column.  What does food have to do with chronic hepatitis C virus (HCV) infection?  Everything.  What we eat can lead to weight problems, fatty liver and type 2 diabetes.  These conditions are associated with a poorer HCV prognosis.  HCV treatment is less likely to be effective for those who are overweight or obese.

Most of us will die with HCV rather than of it.  It makes sense to stack the deck in our favor by making the healthiest choices possible.  Changes in the diet may help or eliminate fatty liver, adult-onset diabetes, and high cholesterol.  Healthy food choices may help us avoid a host of diet and weight-related diseases.

Good nutrition relies on knowing:

•    What to eat
•    How much to eat
•    What is in your food
•    Putting this knowledge into practice

Ask experts what to eat and you will get more responses than there were candidates running for the presidential primaries.  In his book, In Defense of Food, Michael Pollan suggests, “Eat food. Not too much. Mostly plants.” By “eat food,”Pollan advises eating food that hasn’t been processed.  I would add: whenever you can, eat food that is grown locally and make it colorful.  This maximizes your chances of getting adequate nutrition.

Here are resources to help you choose a nutrition plan to suit you:

• Harvard School of Public Health www.hsph.harvard.edu/
nutritionsource/index.html

• Oldways www.oldwayspt.org/
med_pyramid.html

• United States Department of Agriculture (USDA) www.mypyramid.gov

How much to eat is tailored to each person.  Our age, size and activity level influence the amount of food we should consume.  Use a food plan as a guideline.  Never use restaurant portions as an authority on how much to eat or you will supersize yourself into a triple by-pass.  For me, how much to eat is a simple equation.  As long as I am maintaining my weight, I am in the correct range.  If I gain weight it is because I am eating too much.  If I lose weight it is because I have leukemia or a tape worm because it certainly won’t be because I ate too little.

How much we eat is as important as what we eat.  For instance, most of us like ice cream.  There is nothing wrong with an occasional indulgence.  However, few realize that a serving of ice cream is about the size of ½ of a baseball.  A serving of meat is the size of a deck of cards.  Eat a pound of steak and you consume more than 5 servings.

Here are some resources to help you gauge your nutritional needs:

• Aim for a Healthy Weight www.nhlbi.nih.gov/health/public/heart
/obesity/lose_wt/index.htm

This website is sponsored by the National Heart Lung and Blood Institute and has excellent tools.

• USDA’s nutrition information www.nutrition.gov

www.caloriecontrol.org  This website is free of advertising and has useful tools. Don’t be fooled by the “.org” – this is funded by the diet food industry. 

www.caloriesperhour.com  – Another commercial website that provides useful tools.

Knowing what is in food is not always straight-forward.  It is easy when the food comes from the produce section or the bulk bins at the organic grocery store.  When it comes in a container, then there is a food label.  Next month’s column will be devoted to reading labels.  For now, the key point is to pay attention to portion size.  Read the label for how many servings are in a container. For instance, those tiny cartons of ice cream look as if they are the perfect size for one person.  Unfortunately, they usually hold 4 to 6 servings.

Putting this knowledge into use is like any new skill.  It gets easier with practice.  Once I knew what I needed and how to maintain a healthy diet, it became routine.  The challenges are the psychological and social aspects of eating.  Although we eat to live, we also eat to celebrate, to mourn, for comfort and for pleasure.  Sometimes this can get out of hand, especially during holidays. 

When I get off track, I try to get back on as soon as possible.  A long time ago, I gave up food-related guilt and remorse.  This helps me settle back into my routine more quickly. Guilt and remorse made the situation worse.

There are some who try and no matter how hard, they cannot consistently master a plan of healthy eating.  If this is true for you, there is help.  Talk to your medical provider. Check out resources such as Overeaters Anonymous or Food Addicts Anonymous.  There are also for-profit programs that may be right for you.

This is easier said than done. For years, I weighed more than I wanted. I tried to lose weight and keep it off, but it was not until I underwent HCV treatment that I was able to drop to a more comfortable range.  The reason I didn’t regain the weight was because of HCV patients.  I had seen them lose weight during treatment and then regain it back. I vowed to keep it off – to live the words I speak.

Having HCV bestows an opportunity to eat responsibly.  It’s an excuse to put down the fork and pick up the walking shoes.  It’s a reason to celebrate life by not overeating rather than over-indulging.  This Thanksgiving, may you be blessed with health and a full heart without a bulging belly.

 

 


Oct-Sept


Rifaximin Demonstrates Highly Statistically Significant Results In Prevention Of Hepatic Encephalopathy In Pivotal Phase 3 Study

An Effective Strategy For Inhibition Of Cirrhosis

A Novel Therapy For Bleeding Gastric Varices

New Insights Into The Pathogenic Mechanisms Of Liver Cirrhosis With Ascites

New Hope For Patients With Advanced Liver Disease

In Liver Disease Patients Normal ALT Levels May Mask Advanced Fibrosis

Brain Fog Busters

Silymarin Improves Quality of Life During Hepatitis C Treatment


You can visit our forum  as a Guest . If you wish to join our site in order to communicate with us please click here

By joining our forum you will also be able to enter our chat room and post messages.

Video on our Forum : Treatment Cirrhosis-Tp- SVR


AUG


Antiviral Treatment for Cirrhotic Patients

Obesity and Diabetes Predict Liver Disease Progression

New Insights Into The Pathogenic Mechanisms Of Liver Cirrhosis With Ascites
 

Liver damage in hepatitis C patients could be treated with warfarin, says study

Compensated cirrhosis


July-June


Hepatitis C Virus May Need Help Of Enzyme To Cause Liver Disease, Pitt Study Finds

To view this video press conference from the Digestive Diseases Conference you may go here:

http://www.medpagetoday.com/MeetingCoverage/DDW/tb/9448

Selected Hepatitis C Patients with Decompensated Cirrhosis Can Benefit from Interferon-based Therapy prior to Liver Transplantation

Liver Damage In Hepatitis C Patients Could Be Treated With Warfarin, Says Study

Diabetic Patients With Advanced Hepatitis C Have Double The Risk Of Liver Cancer

Elevated Liver Enzymes Linked to Development of Diabetes

Liver Disease Score Predicts Outcome of Variceal Hemorrhage

Alcohol Abuse & Dependence Has Big Impact on Cirrhosis in HIV/HCV Coinfection

 (06-01-08)



May


DDW: Effects of Eltrombopag On Thrombopietin Levels During Antiviral Therapy in HCV Patients with Cirrhosis - (05/21/08)

EASL: Regression of Cirrhosis Occurs & Prevents Death/Events - (05/16/08)

EASL: SVR Can Prevent HCC & Other Complications -

EASL: SVR Reversed Cirrhosis in 21% - (05/16/08)

HALT-C Study Design Flawed -

Study shows positive findings in treating patients with advanced hepatitis C -

The role of nutrition in hepatic encephalopathy

MR Imaging of Hepatocellular Carcinoma in the Cirrhotic Liver: Challenges and Controversies

 


April


HALT-C Study Design Flawed -

Study shows positive findings in treating patients with advanced hepatitis C -

Pegylated Interferon Maintenance Demonstrates Benefits for Hepatitis C Patients with Portal Hypertension

Combination Therapy Improves Survival Time for Patients with Advanced Liver Cancer

Complications of Cirrhosis -- Clinical Insights and Implications for Practice

Osteoporosis and Fractures Missing the Bridge? Commentary -

Two Genetic Variants Found to be Associated with Increased Risk for Osteoporosis and Fracture -

Safety, tolerability, and efficacy of pegylated-interferon alfa-2a plus ribavirin in hcv-related
decompensated cirrhotics.


Ray of hope for cirrhosis

Bone disorders in chronic liver disease

Man-made molecules reverse liver cirrhosis in rats

Liver Failure Treatments and Cirrhosis of the liver

CIRRHOSIS IN CHRONIC HEPATITIS C INFECTION

Risk Of Hepatitis C-Related Liver Damage Increased By Regular Marijuana Use


March-February


Pegylated Interferon plus Ribavirin for Patients with HCV-related Liver Cirrhosis

Patients With Cirrhosis And Gene Variation May Have Elevated Risk Of Liver Tumor

Attention: Extra-Hepatic Manifestation Of Hepatitis C Virus Infection

Increased Oxidative Stress In Decompensated Cirrhotic Patients

Improved 3-variable model to identify cirrhosis

New Upper Limit Defined for Normal ALT in Adolescent Males -

 Cure for Cirrhosis?

Muscular exercise can cause highly pathological liver function tests in healthy men

Patients at Risk for Liver Cancer Should Be Screened With Ultrasound: Presented at ASCO-GI

In Chronic Hepatitis C Silymarin Does Not Affect Virus Activity Or ALT Levels


Jan 2008


Hepatitis C Virus Affects Many Organs And Tissues, Not Just Liver

A Liver Disease Breakthrough

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial

Progressing from Cirrhosis to Liver Cancer May be Genetic


Gene Variation May Elevate Risk Of Liver Tumor In Patients With Cirrhosis

Research Offers Promise for Cirrhosis Treatment

Ursodiol Lowers Liver Enzymes in HCV Study

Interferon Maintenance Therapy and Liver Disease Progression

 


CIRRHOSIS IN CHRONIC HEPATITIS C INFECTION

2009 Research

2008 Research     2007 Research

2006 Research    2005 Research  

2004-2001 Research Archives


copyright © 2003-2008 Janis and Friends Hepatitis C Web Site|  design )by carter

Design downloaded from Zeroweb.org: Free website templates, layouts, and tools.